Advanced search
Start date

From discovery to validation of prognostic candidates for Oral Cancer in liquid biopsies

Grant number: 18/15535-0
Support type:Research Grants - Young Investigators Grants
Duration: August 01, 2019 - July 31, 2023
Field of knowledge:Health Sciences - Medicine
Principal Investigator:Daniela Campos Granato
Grantee:Daniela Campos Granato
Home Institution: Centro Nacional de Pesquisa em Energia e Materiais (CNPEM). Ministério da Ciência, Tecnologia, Inovações e Comunicações (Brasil). Campinas , SP, Brazil
Assoc. researchers:Adriana Franco Paes Leme ; Alan Roger dos Santos Silva ; Marcio Chaim Bajgelman ; Roxane Maria Fontes Piazza ; Wilfredo Alejandro González Arriagada


Squamous Cell Carcinoma (SCC) is the most common type of Oral Cancer (OSCC) and is a malignity derived from the squamous stratified epithelium of the oral mucosa. Regardless of the advances in the treatment of OSCC along the years, the rate of survival is very low, with 50% of the advanced cases dying in the period of 5 years. Besides, the prognosis and treatment strategies are defined mostly based on TNM classification. Thus, the identification of biological signatures may complement the clinical decision. Discovery based proteomics combined with targeted proteomics, associated with Computational Biology are robust techniques currently used to identify, quantify and classify prognostic signatures in different types of cancer. Besides, the original, recent and promising results from the group, especially when evaluating liquid biopsies, reinforce the potential of these strategies. Considering that the most common prognostic factor in cases of patients with SCC involves the lymph node metastasis, this project aims in the discovery phase to (i) characterize the proteins (panel of signatures) with prognosis meaning, extracted from (1) saliva and (2) tear fluid of oral SCC patients and from healthy control individuals; in a second phase (ii) verify signatures, also in plasma, and in a small cohort of patients, through targeted proteomics; and on a third phase (iii) validate the signatures, in a large cohort of patients, for clinical application through targeted proteomics, Immunohistochemistry (IHC) and Enzyme-Linked Immunosorbent Assays (ELISA). The strategy proposed in this project is very promising for the scientific community, in the field of Head and Neck Carcinoma, as well as for proteomics based in mass spectrometry, as demonstrated by the recent work from the group that has been recognized and published in Nature Communications (Carnielli, Macedo, De Rossi, Granato et al., 2018). It is expected that the signature with prognostic value provided from the analysis of liquid biopsies may improve the clinical decision for treatment modalities and, with that, improve the survival and quality of life of the patients. (AU)